Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. (trading symbol: LPTX) on November 2, 2022. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Cambridge, MA. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the company's stock price performance relative to listing requirements.
Material Changes and Events
On November 2, 2022, the company received a deficiency letter from the Nasdaq Listing Qualifications Department. The notification cited that the closing bid price for the company's common stock had been below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). This notification has no immediate effect on the company's listing status.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-calendar-day period to regain compliance, ending on May 1, 2023.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days before the compliance date.
- Secondary Options: If the company fails to regain compliance by May 1, 2023, it may be eligible for an additional 180-day period. Qualification for this extension requires meeting the market value of publicly held shares and other initial listing standards, potentially necessitating a reverse stock split.
- Delisting Risk: If the company fails to regain compliance and is ineligible for an extension, the stock will be subject to delisting. The company may appeal such a determination to a Nasdaq Hearings Panel.
- Management Action: Management intends to monitor the stock price and may consider available options, including a reverse stock split, to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of LPTX common stock to assess proximity to the $1.00 threshold.
- Monitor the company's stock price for 10 consecutive business days to determine if the initial compliance window is met.
- Review future filings for announcements regarding a potential reverse stock split if the initial compliance period expires without success.
- Check the company's market value of publicly held shares to assess eligibility for a second compliance period if needed.